Esperion Therapeutis.Inc. buy Quitte
Start price
20.01.16
/
50%
€14.56
Target price
21.07.16
€17.50
Performance (%)
-32.35%
End price
21.07.16
€9.85
Summary
This prediction ended on 21.07.16 with a price of €9.85. The BUY prediction by Quitte for Esperion Therapeutis.Inc. performed very badly with a performance of -32.35%. Quitte has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 5.992% | 5.992% | 46.769% | -50.457% |
| iShares Core DAX® | 3.002% | 3.742% | 24.169% | 65.664% |
| iShares Nasdaq 100 | 2.966% | 1.308% | 9.141% | 111.170% |
| iShares Nikkei 225® | 5.606% | 4.472% | 21.237% | 55.883% |
| iShares S&P 500 | 2.312% | 1.880% | 6.333% | 67.956% |
Comments by Quitte for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Jammertal ade
irgendwann muss das was werden
(Laufzeit überschritten)